
|Articles|April 1, 2002
- Volume 0 0
Early and Aggressive Intervention in RA Crucial
Advertisement
A recent study conducted at Turku University in Finland highlights the urgency of early and aggressive treatment of rheumatoid arthritis (RA). The study examined the impact of delaying treatment for symptoms on whether disease remission is achieved; it also assessed the efficacy of single-drug therapy vs combination therapy. Researchers found that those in the group whose treatment was delayed fared worst, whereas those who received an aggressive combination-therapy regimen fared best.
Articles in this issue
over 24 years ago
Blood Pressure Drugs May Improve Fitness in the Elderlyover 24 years ago
Fast Facts on Osteoporosisover 24 years ago
Take Tea and See?Higher Bone Densityover 24 years ago
New Fish Advisory Coming for Pregnant Womenover 24 years ago
Fitness Mattersover 24 years ago
Systolic Measurement Better Indicator of Mortality Riskover 24 years ago
Higher Activity = Lower Blood Pressureover 24 years ago
Juan Valdez and Starbucks Would Smileover 24 years ago
ASTHMA Underdiagnosed and Undertreatedover 24 years ago
Pharmacists Important Asthma CounselorsAdvertisement
Related to this article

Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.

A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.

Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.

The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
Tec-Dara Cuts Death Risk 78% Without Raising Fatal Toxicity
5



